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abstract
Introduction The number and lifespan of individuals living with HIV have increased significantly with the
scale-up of antiretroviral therapy. Furthermore, the incidence of breast cancer in women with HIV is
growing, especially in sub-Saharan Africa (SSA). However, the association between HIV infection and
breast cancer is not well understood.
Methods A literature search was performed to identify articles published in journals pertaining to breast
cancer and HIV, with an emphasis on SSA. Selected US-based studies were also identified for comparison.
ResultsAmong the56studies reviewed, the largest studyexamined314patientswithbreast cancerandHIV
in the United States. There is no consensus on whether HIV infection acts as a pro-oncogenic or anti-
oncogenic factor in breast cancer, and itmayhaveno relation to breast cancer.Ahigher incidenceof breast
cancer is reported in high-income countries than in SSA, although breast cancer in SSA presents at a
younger age and at a more advanced stage. Some studies show that patients with breast cancer and HIV
experience worse chemotherapy toxicity than do patients without HIV. Data on treatment outcomes are
limited. The largest study showed worse treatment outcomes in patients with HIV, compared with their
counterparts without HIV.
Conclusion HIV infection has not been associated with different clinical presentation of breast cancer.
However, some evidence suggests that concurrent diagnosis of HIV with breast cancer is associated with
increased therapy-related toxicity and worse outcomes. Systematic prospective studies are needed to
establish whether there is a specific association between breast cancer and HIV.
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INTRODUCTION
The HIV pandemic remains a public health crisis
worldwide. There were 35 million people infected
with HIV in 2013, the majority (71%) of whom
resided in sub-Saharan Africa (SSA).1,2 The ad-
vent and widespread availability of antiretroviral
therapy (ART) has led to both a four-fold decrease
in mortality due to AIDS and a three-fold decrease
in AIDS-defining cancers (ADCs) worldwide.3-6 At
the same time, as the life expectancy and preva-
lence of women living with HIV increases, there
has been a three-fold increase in the incidence of
certain non-AIDS–defining cancers (NADCs),
such as lung cancer, Hodgkin lymphoma, squa-
mous cell carcinoma, testicular cancer, and
esophageal cancer.4-6 SSA has experienced sim-
ilar trends, with a declining incidence of ADCs
such as Kaposi sarcoma in Botswana and an
increase in NADCs in Tanzania.7-10
Breast cancer is themost common cancer among
all women in the general population worldwide.11
Women living in low- and middle-income coun-
tries make up 53% of new cancer cases and 62%
of cancer-related mortality globally.11-13 Among
women with HIV worldwide, breast cancer is the
most common typeofNADC, representingapprox-
imately 12%of all newcancercasesand25%ofall
cancers.11 In regions such as SSA, with the prev-
alence and increased survival of HIV-infected in-
dividuals and the increasing incidence of breast
cancer, a growing number of women are being
affected with both diagnoses. Although the onco-
logic relationship between HIV/AIDS and certain
cancers is well understood, there is little evidence
about breast cancer among individuals with HIV
infection. The incidence of breast cancer in Africa
is estimated to double by 2050, and as such,more
information is needed to guide treatment in this
unique population of women affected by both HIV
and breast cancer.
This review summarizes findings from published
studies about the pathogenesis, incidence, clin-
ical presentation, and treatment outcomes of
patients with HIV with a concurrent breast can-
cer diagnosis. Unfortunately, there are numer-
ous inadequacies in data collection, storage, and
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analysis systems for studying breast cancer and
HIV inSSA.Wemake recommendations for further
interventions and future studies.
METHODS
We searched the PubMed database up to March
2016. Our primary search strategy combined the
following terms with Boolean operators: breast
neoplasm; breast malignancy; breast cancer; hu-
man immunodeficiency virus; HIV; Africa; SSA;
and Africa, south of Sahara. Our search included
terms focusing on studies in SSA because of the
high burden of HIV and breast cancer in this
region, although selected US studies were also
included for comparison, because this is where
the largest HIV-infected cohorts can be identified.
The search was limited to studies performed in
humans. As Africa is a trilingual continent, publi-
cations were not excluded by language. All publi-
cation types were included in this first screen to
ensure that no relevant data were missed. All titles
and abstracts from each of the searches were
examined. The full text of each article was obtained
and reviewed if the title or abstract discussed HIV
and breast cancer. Articles that discussedHIV and
cancer, but not breast cancer, or discussed breast
cancer without HIV were excluded.
One reviewer (S.G.) extracted data on publication
details (year, authors, study country), study details
(study duration, study population), and signifi-
cant findings. An independent reviewer (N.M.Z.)
extracted data from10%of the articles for external
validity; disagreements were discussed, and a
consensus was agreed on.
We identified three thematic areas: epidemiologic
characteristics (incidence), pathologic character-
istics (viral association, genetic association, effects
of HIV treatment), and clinical characteristics
(clinical presentation, treatmentmodalities, and
outcomes). Results are summarized according to
these thematic areas and are presented as global
findings—including in the United States, as well as
Africa-specific findings. We obtained additional in-
formation on global breast cancer incidence, HIV
incidence, morbidity, and mortality data from the
International Agency for Research on Cancer and
Global Health Observatory websites.
A limitation we recognize in this review is the use
of the term SSA to refer to all the SSA countries
as one group, despite the heterogeneity of the
population of the continent in race/genetics and
social factors. However, with the limited data on
the region, necessity requires that we group
them together.
RESULTS
The initial search yielded 104 titles. After evaluat-
ing for relevance, 88 abstracts were selected for
further review (Fig1). Theauthors reviewed the full
text and identified 56 articles that were relevant to
the subjectmatter. This review summarizes breast
cancer and HIV/AIDS literature from the selected
articles (Data Supplement).
Incidence of Breast Cancer in IndividualsWith HIV
Marked variation exists in the reported incidence
of breast cancerworldwide—from95 to 100cases
per 100,000 persons in North America, Northern
Europe, and Australia to 13.5 to 30 per 100,000
women in SSA.11,14,15 Breast cancer is less com-
mon in black women than in white women in SSA,
with an age-standardized rate of 11.3 per 100,000
in central Africa and 70.2 per 100,000 for white
women in South Africa.16 The breast cancer in-
cidence in Africa continues to increase and is
projected to double by 2050.17-19
AmongpatientswithHIV, AmericanandEuropean
cohorts have shown a drop in standardized in-
cidence ratios of breast cancer in the post-ART
era, likely because of greater health care linkage
and access to screening through HIV care pro-
grams.20-27 Data from 937 patients in Tanzania
also show a significant drop in the incidence of
breast cancer in HIV-infected women.28,29
Pathologic Association Between HIV and Breast
Cancer
Breast cancer develops as a result of the com-
plex interplay of host, genetic, metabolic, immu-
nologic, and environmental factors, although
several malignancies have a well-defined associ-
ationwith viruses (eg, Kaposi sarcomaandhuman
herpesvirus 8).30 Breast cancer has no estab-
lished viral (including HIV) associations, although
several have been suggested.31-34
HIV and breast cancer molecular pathways and
genetic expression. Evaluation of the genes and
molecular pathways involved in HIV infection
and breast cancer has revealed that HIV infection
and breast cancer might be specifically associ-
ated.However, it is disputedwhetherHIVconfersa
protective, detrimental, or neutral effect on breast
cancer development.
A number of studies have suggested an acceler-
ating or detrimental effect of HIV on breast cancer.
Gene-disease association network (GDN) studies
have been used to probe the relationship between
HIV and breast cancer.35 In the GDN, two
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disorders are interrelated if they share at least one
commongenemutation.Microarray data revealed
that HIV infection and breast cancer share 17
genes, of which 10 are overexpressed and seven
are underexpressed in both diseases.36 Other
studies have demonstrated similar genetics, sig-
nalingpathways, proteins, and receptors common
to both HIV and breast cancer.35,37 The common
expression of genes and receptors indicates pos-
sible ways in which HIV might directly modify the
natural history of breast cancer, but does not
establish a causative link. However, there is evi-
dence thatHIV infectionpromotes tumor growth via
immune signaling, angiogenesis, andmetastasis in
breast cancer.36,38-48 These findings may provide
the causative link between breast cancer and HIV.
In contrast, a few studies suggest a protective
effect of HIV on breast cancer. HIV infection
activates cell death pathways, which may lead
to the decreased cancer burden in these pa-
tients.49 In addition, an in vitro study suggests that
HIV replication in human breast cells hinders their
growth by affecting growth factor receptors, sug-
gesting that HIV infection may counteract onco-
genesis in breast cancer cells.50
HIV-associated comorbidities and breast cancer.
Finally, there are studies suggesting development
of breast cancer in patients with HIV through
comorbidities, such as metabolic syndrome due
toART35,51,52 associatedwithHIVandHIV-related
therapy. Several breast cancer risk factors are
associated with metabolic syndrome, such as
abdominal obesity, high blood glucose level, high
blood pressure, high triglyceride levels, and low
high-density lipoprotein levels.52HIV infectionand
ART are known to be associated with a variety of
metabolic changes and disorders, including met-
abolic syndrome. Several published studies found
an overall increase in the incidence of metabolic
syndrome in patients with HIV receiving ART over
time,51 making this comorbidity particularly rele-
vant for patients with HIV and breast cancer.
Clinical Characteristics
Presentation.On the basis ofmost series available,
the median age at diagnosis for patients with
breast cancer without HIV in high-income popu-
lations is 61 years, compared with 10 to 15 years
younger in patients with HIV.53-60 However, Shiels
et al61 reported that in their cohort of 110 US
patients, age at breast cancer diagnosis was sim-
ilar in the AIDS and general populations. In high-
income countries, there is controversy regarding
the effect of HIV on age at presentation. Patients
with breast cancer in SSA generally present
at a relatively younger age regardless of HIV
status.62-64 The overall mean age of presentation
in West African women is between 35 and 45
years, 10 to 15 years earlier than women in
high-income countries.14,65,66 Similarly, a 3-year
retrospective review of 374 patients with breast
cancer in Kenya showed a median age of 44
years,64,67-69 and the mean age in a Tanzanian
cancer registry is 44.7 years.28 A 2-year study at
the Tygerberg Academic Hospital in Cape Town,
South Africa, reported trends similar to the pop-
ulation in the high-income countries, with a me-
dian age at presentation of 56 years for patients
without HIV compared with 42 years for patients
with HIV (P , .001).70
Patients with breast cancer in high-income coun-
tries predominantly present with early-stage dis-
ease. Patients with HIV and breast cancer in the
United States present with stage distribution sim-
ilar to their seronegative counterparts57,71-73: 60%
of all patients present with stage I disease, 33%
with stage II or III disease, and 5% with stage IV
disease.74 In addition, the distribution of histologic
subtypes of breast cancers was found to be in-
dependent of HIV status.75,76 However, few case
reports ofpatientswithHIVandbreast cancerhave
noted a more disseminated breast cancer and
marked aggressiveness despite favorable biologic
prognostic parameters.55,56,77,78
In SSA, amajority of patients present with advanced-
stagedisease,with89.6%and72.8%ofpatientswith
breast cancer in Kenya and Nigeria, respectively,
Titles
identified
through
initial search
(N = 104)
Abstracts
identified for
full text
review
( n = 88)
Articles
included in
the final
review
(n = 56)
Epidemiology
(n = 17)
Pathophysiology
(n = 8)
Clinical
(n = 31)
Fig 1 –
Results of systematic
search, screening, anddata
extraction for review of
breast cancer and HIV.
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presentingwithadvanced-stagedisease.67,68Astudy
byVorobiof et al 16 showed that black femalepatients
in South Africa presented with advanced-stage dis-
ease (77.7%) at a higher rate than white female
patients (30.7%). Table 1 lists the data for clinical
presentation in the studies reviewed.3,67,68,70
Molecular subtypes of breast cancer tumors in
patients with HIV infection are similar to those of
geographically matched patients with breast
cancer without HIV in high-income countries
and SSA. The University of Maryland cohort of
US patients with breast cancer had primarily
estrogen receptor– and progesterone receptor–
positive disease (72% and 61%, respectively),
which was similar in patients with HIV, except
for human epidermal growth factor receptor 2
overexpression, which was higher in the HIV
subset.57 Similarly, among South African pa-
tients, approximately two thirds of breast tumors
were hormone receptor–positive regardless of
HIV status.3,70,79
Studies examining the effect of HIV-related immu-
nosuppression on the risk of breast cancer in
patients with HIV are scant. Some suggest that
patients with HIV may develop breast cancer due
to impaired immune surveillance,80,81 although a
few small studies have shown no relationship
between immunosuppression and breast can-
cer.82-84 In the University of Maryland study,
the median CD4 count was 437.5 cells/mL.57
Similarly, a median CD4 count of 424 cells/mL
was noted in an Italian cohort,59 and 50% of
South African patients with breast cancer and HIV
had CD4 counts between 200 and 499 cells/mL.3
A case report by Garc ı´a-Tejedor et al85 of a
patient with HIV and hepatitis C virus infec-
tion even documented a CD4 count as low as
181 cells/mL. CD4 count was not associated with
Table 1 – Demographic and Clinical Characteristics of Patients With Breast Cancer for Studies Included in the Review of Breast Cancer and HIV
(presented by study)
Study Country
No. of
Patients
with Breast
Cancer
No. of
Patients with
HIV and
Breast
Cancer (%)
Patients With
Advanced-
Stage Breast
Cancer, %
Median
Age at
Diagnosis,
years
Median Age
at Diagnosis
of Patients
With HIV,
years
Receptor
Status in
Patients
Without HIV,
%
Receptor
Status in
Patients
With HIV, %
Differences
in Receptors
on the Basis
of HIV Status
Hurley et al72 US 20 20 (100) 10 44
El-Rayes et al73 US 38 38 (100) 20
Singh et al57 US 18 18 (100) 28 48 ER: 72 Higher
incidence
of HER2-
positive
status in
patients
with HIV
PR: 61
HER2: 44
TNBC: 17
Othieno-Abinya
et al67
Kenya 250 0 (0) 89.6 44
Ikpat66 Nigeria 300 0 (0) 42.7
Adebamowo and
Adekunle68
Nigeria 250 0 (0) 72.8 43
Anyanwu62 Nigeria 179 0 (0) 72 46.9
Cubasch et al3 Soweto,
South
Africa
1,092 765 (70) 50 ER: 58 ER: 62 No difference
PR: 47 PR: 52
HER2: 22 HER2: 27
TNBC: 19 TNBC: 16
Langenhoven
et al70
Cape
Town,
South
Africa
586 31 (5) 55 56 42 ER: 64 ER: 52 No difference
PR: 51 PR: 29
HER2: 36 HER2: 32
TNBC: 16 TNBC: 16
Amir et al28 Tanzania 937 0 (0) 44.7
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNBC, triple-negative breast cancer.
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breast cancer stage at presentation, subtype, or
tumor grade in these studies.
In summary, the average age of breast cancer
diagnosis is lower in SSA women, compared with
their counterparts in high-income countries. Al-
though findings from cohorts in high-income
countries suggest an earlier age at diagnosis for
patients with HIV and breast cancer compared
with those without HIV, those studies were gener-
ally small and inconclusive.57 Cancer stage at
presentation for patients with breast cancer in
the United States is similar in patients both with
and without HIV.57,71 In SSA, age and stage at
presentation of patients with and without HIV and
with breast cancer were similar.79 Table 1 lists
the data for clinical presentation in the studies
reviewed.3,67,68,70
Treatment and tolerability. Suneja et al86 analyzed
registry data from three US states (Connecticut,
Michigan, and Texas) involved in the linkage of
cancer and HIV/AIDS registries from 1996 to
2010. They identified 3,045 adults with concur-
rent HIV infections and cancer diagnoses, of
whom 108 had HIV and breast cancer. Their re-
sults showed that for most cancers, a significantly
higher proportion of individuals with HIV did not
receive cancer treatment. However, in the subset
of patients with HIV and breast cancer, there was
no statistically significant difference in receipt of
standard therapy for both local and advanced
breast cancer compared with matched patients
without HIV. The percentage of patients without
treatment was 9% and 4.7% in patients with and
without HIV, respectively. The results were the
same in the pre-ART and ART era.86 The major
limitations for the study were missing data regard-
ing some prognostic indicators for therapy, as well
as details on treatment, with first course of treat-
ment definedas any treatment commencedwithin
6 months of the initial diagnosis.86
In patients with HIV receiving ART and chemo-
therapy, studies in high-income countries have
shown that potential treatment interactions may
result in worse adverse events in patients with HIV
receiving chemotherapy compared with their sero-
negative counterparts.87 Hurley et al72 published a
retrospective review on 20 patients with HIV and
breast cancer in Florida and found that chemother-
apy was poorly tolerated in patients withHIV; grade
3 and 4 myelosuppression was seen in five of the
seven patients treated with anthracycline-based
chemotherapy. In that study, two patients who
completed adjuvant therapy then progressed to
advanced AIDS. In contrast, patients who received
surgery and hormonal therapy alone experienced
fewer adverse events compared with patients
who received chemotherapy.72 Similarly, El-Rayes
et al73 showed in a series of five premenopausal
women in Michigan that receipt of chemotherapy
was complicated by neutropenia in four of the five
patients who received chemotherapy. The rate of
neutropenia andneutropenic fever inpatientswith-
out HIV was reported to be 3% to 15%.88 The
authors also found progression to AIDS in two of
38 patients, with a notable increase in viral load or
decrease in CD4 count despite concurrently re-
ceiving ART with chemotherapy.73 This trend was
also observed in a retrospective study in Maryland
by Singh et al57 evaluating data on 18 patients with
ductal carcinoma in situ or breast cancer and HIV/
AIDS. They found grade 2 and 3 infectious toxicity in
50% of patients and 70% of those requiring treat-
mentdelaysanddose reduction in chemotherapy57;
only 60% of patients with HIV and breast cancer
overall completed chemotherapy. Parameswaran
et al89 similarly reported that 56% of patients with
HIV and breast cancer in New York required treat-
ment delays and dose reduction in chemotherapy,
compared with 30% of patients without HIV. Al-
though CD4 count in patients with HIV is not shown
to be associated with age and stage at presentation,
some have speculated that CD4 count at diagnosis
may dictate chemotherapy tolerance.90
In contrast, Langenhoven et al70 reported that in a
South African cohort, more than 84% of patients
with breast cancer, including 19 patients with HIV
and breast cancer, who initiated systemic chemo-
therapy completed it without serious toxicity, re-
gardless of HIV status. This was found despite a
mean decline in CD4count during chemotherapy,
from 477 cells/mL to 333 cells/mL. There was no
statistically significant difference in hematologic
toxicity requiring dose modification. However,
grade 3 or 4 lymphocytopenia developed only in
the patients withHIV (26.4%;P= .001). The study
did not report baseline lymphocyte count for pa-
tients with HIV versus those without HIV before
initiating systemic therapy. In addition, of 19 pa-
tients with HIV and breast cancer included in the
toxicity analysis, there were no data on how many
patients were receiving ART concurrently with
chemotherapy or details of the ART regimen.70
Toxicities associatedwith chemotherapy are listed
by study in Table 2.
There are limited studies examining treatment
outcomes with surgery and radiation therapy
in patients with HIV/AIDS and breast cancer.
Hurley et al72 noted that patients with HIV who
received breast surgery without chemotherapy
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experienced fewer adverse events. Buehrer et al91
found that surgicalmanagementwas not associated
with complications in patients with HIV in North
Carolina. Radiotherapy seems to be well tolerated
on the basis of a case report of this subpopulation.75
However, rigorous data are lacking in this area.
Overall, these findings suggest that HIV/AIDS may
negatively affect chemotherapy tolerability with a
greater degree of immunosuppression observed
with concurrent ART, in particular, zidovudine
and protease inhibitors. This in turn may reduce
treatment efficacy and treatment adequacy through
poor adherence, dose adjustments, treatment de-
lays, and/or early discontinuation of therapy.73,89,92
Outcomes. The largest study evaluating survival in
patients with HIV and cancer used data from six
US states participating in a linkage of cancer and
HIV/AIDS registries and had a total of 1,816,461
patients with cancer, including 6,459 (0.36%)
with HIV.93 Cancer diagnosis was limited to adults
with 14 common ADCs and NADCs occurring
between 1996 and 2010. A total of 314 patients
with HIV and breast cancer were identified. The
authors reported that patients with HIV and
NADCs are more likely to die as a result of their
cancer than patients without HIV. This was in-
dependent of cancer stage or receipt of cancer
treatment. Specifically for breast cancer, the haz-
ard ratio was 4.62 (95% CI, 3.92 to 5.45) for all-
causemortality and2.61 (95%CI, 2.06 to3.31) for
breast cancer–specificmortality. ART treatment in
the people living with HIV was not reported; how-
ever, cancer-specific mortality limited to the ART
era was 3.43 (95% CI, 2.35 to 5.01) for people
living with HIV and breast cancer. This investiga-
tion is the largest systematic review of survival
within this subpopulation, but its limitations in-
clude incomplete data on HIV viremia and mea-
sures of immunosuppression.93
Small studies in SSA have not shown a difference
in breast cancer outcomes when comparing pa-
tients with HIV with those without HIV. Coghill
et al94 conducted a retrospective study using
the Kampala cancer registry. Among those with
HIV infection (24 of 220; 10.9%), they found a
more than two-fold increased risk of death within
1 year of a breast cancer diagnosis compared with
individualswithoutHIV. Thedata for breast cancer
alone did not show a significant difference in the
hazard ratio for 1-year survival. This study was
limited by the small population of patientswithHIV
and breast cancer, which may have affected the
ability to achieve a statistically significant difference
insurvivalwithin thisgroup.Other limitations include
incomplete data on cancer stage at presentation,
treatment, and degree of immunosuppression.94
In contrast, Gotti et al95 noted an improvement in
overall survival in ADCs compared with NADCs
in the ART era in the United States. The overall
median survival was 1.6 years for NADCs and
3.4 years for ADCs. Specifically in patients with
breast cancer, considered an NADC, no signifi-
cant association was noted between HIV clinical
variables (ie, combination antiretroviral therapy,
CD4, viral load) and risk of mortality.95 These
findings suggest that patients with HIV and breast
cancer may have an increased risk of cancer-
specific mortality compared with patients without
HIV, although these studies hadmany limitations.
In conclusion, the prolonged survival and increas-
ing prevalence of HIV among women globally in
conjunction with the increasing burden of breast
cancer worldwide has led to an emerging and
poorly understood subpopulation of patients with
HIV and breast cancer. Although this increased life
expectancy for patients with HIV has led to many
otherNADCs tobedescribed, thereare limiteddata
on the relationshipbetweenHIVandbreast cancer.
Table 2 – Chemotherapy Toxicity Characteristics in the Studies Included in the Review of Breast Cancer and HIV (presented by study)
Study
Total No. of
Patients
WithBreast
Cancer
No. of Patients
Receiving
Chemotherapy
Patients With
Grade 3
Hematologic
Toxicity, %
Patients
With Grade
2 & 3
Infectious
Toxicity, %
Patients Who
Completed
Chemotherapy,
%
Patients
Receiving
Chemotherapy
Requiring
Treatment
Delays or Dose
Reductions, %
No. of
Patients
Whose
Disease
Progressed
to
Advanced
AIDS
Patients Developing
Grade 3 or 4
Myelosuppression,%
Singh et al57 18 10 40 50 60 70
Langenhoven
et al70
31 19 26.4
(lymphocytopenia)
Hurley et al72 20 7 2 71.4
El-Rayes et al73 5 5 80 (neutropenia)
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The natural history of breast cancer in individuals
with HIV is poorly understood, and it is unknown
whether viral infection is a protective factor for
breast cancer development or a risk factor for
accelerated oncogenesis. A definitive link be-
tween these two disease processes remains to
be established. Presentation of breast cancer in
patients with HIV in SSA has age and stage distri-
bution, as well as molecular subtypes, similar to
that in high-income countries.79 Data from high-
incomecountries’cohorts suggest anearlier ageat
diagnosis in patients with HIV and breast cancer
compared with their counterparts without HIV in
several small inconclusive investigations.57,59
The largest series to investigate cancer out-
comes was a retrospective analysis of registry
data from the United States.93 Although the
results provide more insight into outcomes
among patients with breast cancer and HIV
infection, follow-up and treatment data were
missing for a significant number of patients in
this cohort. Similarly, many of the studies in SSA
had poor data collection, storage, and analysis
systems. Larger prospectivemulticenter and cross-
border cohort studies of patients with HIV in SSA,
especially in those countries that have a high HIV
disease burden, are needed to establish the true
prevalence and incidence of concurrent breast
cancerandHIV infectionand to identify interactions
between these diseases. The impact of immunobi-
ology on outcomes also deserves further explora-
tion. In addition, screening, diagnosis, access to
uninterrupted treatments, palliative care services,
and rehabilitationofpatientswhohavesurvivedHIV
and breast cancer are other aspects of health de-
livery systems in the SSA countries that warrant
further attention and study. Such information can
help to guide the design of safe treatment algo-
rithms for patients with HIV and breast cancer to
achieve improved outcomes in this important and
emerging population in our global community.
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